NASDAQ:PRLD Prelude Therapeutics (PRLD) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free PRLD Stock Alerts $4.00 -0.28 (-6.54%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$3.99▼$4.3750-Day Range$3.44▼$5.6352-Week Range$1.66▼$6.14Volume40,809 shsAverage Volume39,355 shsMarket Capitalization$219.72 millionP/E RatioN/ADividend YieldN/APrice Target$5.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Prelude Therapeutics alerts: Email Address Prelude Therapeutics MarketRank™ Stock AnalysisAnalyst RatingReduce1.67 Rating ScoreUpside/Downside31.3% Upside$5.25 Price TargetShort InterestBearish2.43% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.84) to ($1.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.16 out of 5 starsMedical Sector769th out of 914 stocksPharmaceutical Preparations Industry365th out of 427 stocks 2.8 Analyst's Opinion Consensus RatingPrelude Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoveragePrelude Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Prelude Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.43% of the float of Prelude Therapeutics has been sold short.Short Interest Ratio / Days to CoverPrelude Therapeutics has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Prelude Therapeutics has recently increased by 4.40%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPrelude Therapeutics does not currently pay a dividend.Dividend GrowthPrelude Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRLD. Previous Next 1.3 News and Social Media Coverage News SentimentPrelude Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Prelude Therapeutics this week, compared to 1 article on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prelude Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders79.54% of the stock of Prelude Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.72% of the stock of Prelude Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Prelude Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Prelude Therapeutics are expected to decrease in the coming year, from ($1.84) to ($1.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prelude Therapeutics is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prelude Therapeutics is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrelude Therapeutics has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Prelude Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss Ratings[URGENT] DO NOT Touch These AI Stocks!Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap. But is this AI rally over?Click here for our #1 AI Stock for 2024 and Beyond About Prelude Therapeutics Stock (NASDAQ:PRLD)Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.Read More PRLD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRLD Stock News HeadlinesMay 14, 2024 | americanbankingnews.comPrelude Therapeutics (NASDAQ:PRLD) Stock Price Up 1.9%May 11, 2024 | msn.comPrelude Therapeutics to Showcase at Citizens JMP Life Sciences ConferenceMay 10, 2024 | msn.comPrelude Therapeutics Progresses in Cutting-Edge Cancer Treatment DevelopmentMay 9, 2024 | globenewswire.comPrelude Therapeutics to Participate in Citizens JMP Life Sciences ConferenceMay 8, 2024 | finanznachrichten.dePrelude Therapeutics, Inc.: Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prelude Therapeutics on Strong Financials and Promising Clinical ProspectsMay 7, 2024 | investorplace.comPRLD Stock Earnings: Prelude Therapeutics Beats EPS for Q1 2024May 7, 2024 | globenewswire.comPrelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 13, 2024 | finance.yahoo.comSeveral Insiders Invested In Prelude Therapeutics Flagging Positive NewsApril 9, 2024 | globenewswire.comPrelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual MeetingMarch 30, 2024 | morningstar.comPrelude Therapeutics Inc Ordinary Shares PRLDMarch 16, 2024 | finance.yahoo.comPRLD Apr 2024 5.000 callMarch 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Clearside Biomedical (CLSD) and Prelude Therapeutics (PRLD)March 5, 2024 | globenewswire.comPrelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual MeetingFebruary 29, 2024 | globenewswire.comPrelude Therapeutics to Participate in Barclays Global Healthcare ConferenceFebruary 17, 2024 | finance.yahoo.comHere's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn SituationFebruary 17, 2024 | msn.comNew Accounting & Financial Operations Risk for Prelude Therapeutics, Inc. – What’s the Latest?February 16, 2024 | msn.comPrelude Therapeutics files to sell 7.94M shares for holdersFebruary 16, 2024 | markets.businessinsider.comPrelude Therapeutics Incorporated Registered ShsFebruary 15, 2024 | finance.yahoo.comPrelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024February 15, 2024 | globenewswire.comPrelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024February 5, 2024 | seekingalpha.comPrelude Therapeutics: Interesting Pipeline That Is Too Early To Warrant My BuyJanuary 14, 2024 | finance.yahoo.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) is definitely on the radar of hedge funds investors who own 33% of the companyDecember 19, 2023 | msn.comMorgan Stanley Downgrades Prelude Therapeutics (PRLD)December 19, 2023 | markets.businessinsider.comMorgan Stanley Downgrades Prelude Therapeutics: Here's What You Need To KnowSee More Headlines Receive PRLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today5/19/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PRLD CUSIPN/A CIK1678660 Webwww.preludetx.com Phone302-467-1280FaxN/AEmployees128Year FoundedN/APrice Target and Rating Average Stock Price Target$5.25 High Stock Price Target$7.00 Low Stock Price Target$4.00 Potential Upside/Downside+31.3%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-121,830,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-52.97% Return on Assets-47.20% Debt Debt-to-Equity RatioN/A Current Ratio11.64 Quick Ratio11.64 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.84 per share Price / Book1.04Miscellaneous Outstanding Shares54,930,000Free Float11,239,000Market Cap$219.72 million OptionableOptionable Beta1.56 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Krishna Vaddi D.V.M. (Age 58)Ph.D., Founder, CEO & Director Comp: $905.92kDr. Edna Huang M.D. (Age 51)President & Chief Medical Officer Comp: $865.63kMr. Bryant David Lim J.D. (Age 53)Interim CFO, Chief Legal Officer & Corporate Secretary Comp: $586.42kMs. Aimee Crombie Ph.D.Senior VP and Head of Strategic Planning & OperationsDr. Madhu Pudipeddi Ph.D.Senior Vice President of Technical OperationsDr. Peggy A. Scherle Ph.D. (Age 62)Chief Scientific Officer Comp: $868.62kLindsey TrickettVice President of Investor RelationsMs. Michele Porreca M.B.A.Chief People OfficerDr. Andrew P. Combs Ph.D. (Age 57)Executive VP & Chief Chemistry Officer Comp: $562.46kMr. Naveen Babbar Ph.D.Senior Vice President of Translation MedicineMore ExecutivesKey CompetitorsscPharmaceuticalsNASDAQ:SCPHProQR TherapeuticsNASDAQ:PRQRCapricor TherapeuticsNASDAQ:CAPRGossamer BioNASDAQ:GOSSRigel PharmaceuticalsNASDAQ:RIGLView All CompetitorsInsiders & InstitutionsKennedy Capital Management LLCBought 25,035 shares on 5/16/2024Ownership: 0.059%Price T Rowe Associates Inc. MDSold 100,766 shares on 5/15/2024Ownership: 2.239%Vanguard Group Inc.Bought 10,143 shares on 5/10/2024Ownership: 2.417%Acadian Asset Management LLCBought 6,615 shares on 5/10/2024Ownership: 0.053%Krishna VaddiBought 1,000 shares on 5/24/2023Total: $5,010.00 ($5.01/share)View All Insider TransactionsView All Institutional Transactions PRLD Stock Analysis - Frequently Asked Questions Should I buy or sell Prelude Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prelude Therapeutics in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" PRLD shares. View PRLD analyst ratings or view top-rated stocks. What is Prelude Therapeutics' stock price target for 2024? 3 Wall Street analysts have issued 12-month price targets for Prelude Therapeutics' stock. Their PRLD share price targets range from $4.00 to $7.00. On average, they anticipate the company's share price to reach $5.25 in the next twelve months. This suggests a possible upside of 31.3% from the stock's current price. View analysts price targets for PRLD or view top-rated stocks among Wall Street analysts. How have PRLD shares performed in 2024? Prelude Therapeutics' stock was trading at $4.27 at the start of the year. Since then, PRLD stock has decreased by 6.3% and is now trading at $4.00. View the best growth stocks for 2024 here. When is Prelude Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our PRLD earnings forecast. How were Prelude Therapeutics' earnings last quarter? Prelude Therapeutics Incorporated (NASDAQ:PRLD) released its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.05. When did Prelude Therapeutics IPO? Prelude Therapeutics (PRLD) raised $149 million in an initial public offering on Friday, September 25th 2020. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities acted as the underwriters for the IPO. Who are Prelude Therapeutics' major shareholders? Prelude Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.42%), Price T Rowe Associates Inc. MD (2.24%), Kennedy Capital Management LLC (0.06%) and Acadian Asset Management LLC (0.05%). Insiders that own company stock include Andrew Combs, Brian Piper, Christopher Pierce, David J Mauro, David J Mauro, Deborah Morosini, Jane Huang, Krishna Vaddi, Laurent Chardonnet, Orbimed Advisors Llc and Peggy Scherle. View institutional ownership trends. How do I buy shares of Prelude Therapeutics? Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRLD) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetry41 banks launch ‘crypto dollar’Stansberry ResearchCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceProtect Your Bank Account Before It’s Too LateWeiss RatingsHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
